title: Crizotinib versus platinum-based double-agent chemotherapy as the first line treatment in advanced anaplastic lymphoma kinase-positive lung adenocarcinoma.
abstract: BACKGROUND
  To explore the efficacy and safety of crizotinib versus platinum-based double agent chemotherapy as the first-line treatment in patients with advanced anaplastic lymphoma kinase (ALK)-positive lung adenocarcinoma.
  
  
  METHODS
  We retrospectively analyzed data from 19 patients with advanced ALK-positive lung adenocarcinoma who had received no previous systemic treatment for advanced disease. Seven patients received oral crizotinib at a dose of 250 mg twice daily; 12 patients were administered standard chemotherapy (pemetrexed, paclitaxel, vinorelbine or gemcitabine plus either cisplatin or carboplatin) every three weeks for up to six cycles. The primary endpoint was overall response rate (ORR), disease control rate (DCR), and safety.
  
  
  RESULTS
  The ORR was significantly higher with crizotinib than with chemotherapy (83.3% in the crizotinib vs. 25.0% in the chemotherapy group, P < 0.05); the DCRs were 100% and 75%, respectively (P < 0.05). The common adverse events associated with crizotinib were visual abnormality and diarrhea, whereas those associated with chemotherapy were neutropenia and nausea. In the crizotinib group, liver aminotransferase elevation (adverse events grade 3 or 4) occurred in one patient (14.3%). In the chemotherapy group, the same grade neutropenia adverse event occurred in two patients (16.6%). The incidence of treatment-related grade 3 or 4 adverse events was similar in both groups. Compared with chemotherapy, crizotinib was associated with a greater reduction in lung cancer symptoms and a greater improvement in quality of life.
  
  
  CONCLUSIONS
  As a first-line treatment, crizotinib was superior to platinum-based double chemotherapy in patients with previously untreated advanced ALK-positive lung adenocarcinoma. Therefore, crizotinib is an optimal therapy as a first-line treatment in these patients.
authors.affiliation: Department of Medical Oncology Beijing Chest Hospital Beijing Tuberculosis and Thoracic Tumor Research Institute Capital Medical University Beijing China.
authors.forename: Quan
authors.initials: Q
authors.lastname: Zhang
authors.affiliation: Department of Medical Oncology Beijing Chest Hospital Beijing Tuberculosis and Thoracic Tumor Research Institute Capital Medical University Beijing China.
authors.forename: Na
authors.initials: N
authors.lastname: Qin
authors.affiliation: Department of Medical Oncology Beijing Chest Hospital Beijing Tuberculosis and Thoracic Tumor Research Institute Capital Medical University Beijing China.
authors.forename: Jinghui
authors.initials: J
authors.lastname: Wang
authors.affiliation: Department of Medical Oncology Beijing Chest Hospital Beijing Tuberculosis and Thoracic Tumor Research Institute Capital Medical University Beijing China.
authors.forename: Jialin
authors.initials: J
authors.lastname: Lv
authors.affiliation: Department of Medical Oncology Beijing Chest Hospital Beijing Tuberculosis and Thoracic Tumor Research Institute Capital Medical University Beijing China.
authors.forename: Xinjie
authors.initials: X
authors.lastname: Yang
authors.affiliation: Department of Medical Oncology Beijing Chest Hospital Beijing Tuberculosis and Thoracic Tumor Research Institute Capital Medical University Beijing China.
authors.forename: Xi
authors.initials: X
authors.lastname: Li
authors.affiliation: Department of Medical Oncology Beijing Chest Hospital Beijing Tuberculosis and Thoracic Tumor Research Institute Capital Medical University Beijing China.
authors.forename: Jingying
authors.initials: J
authors.lastname: Nong
authors.affiliation: Department of Medical Oncology Beijing Chest Hospital Beijing Tuberculosis and Thoracic Tumor Research Institute Capital Medical University Beijing China.
authors.forename: Hui
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Department of Medical Oncology Beijing Chest Hospital Beijing Tuberculosis and Thoracic Tumor Research Institute Capital Medical University Beijing China.
authors.forename: Xinyong
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Department of Medical Oncology Beijing Chest Hospital Beijing Tuberculosis and Thoracic Tumor Research Institute Capital Medical University Beijing China.
authors.forename: Yuhua
authors.initials: Y
authors.lastname: Wu
authors.affiliation: Department of Medical Oncology Beijing Chest Hospital Beijing Tuberculosis and Thoracic Tumor Research Institute Capital Medical University Beijing China.
authors.forename: Shucai
authors.initials: S
authors.lastname: Zhang
keywords: Anaplastic lymphoma kinase; first‐line treatment; non‐small cell lung cancer; targeted therapy
references.citation: Lancet Oncol. 2012 Oct;13(10):1011-9
references.pmid: 22954507
references.citation: PLoS One. 2013;8(1):e52093
references.pmid: 23341890
references.citation: N Engl J Med. 2014 Dec 4;371(23):2167-77
references.pmid: 25470694
references.citation: Nat Rev Clin Oncol. 2012 Apr 03;9(5):268-77
references.pmid: 22473102
references.citation: Cancer. 2013 Apr 15;119(8):1467-77
references.pmid: 23280244
references.citation: J Thorac Oncol. 2014 Jan;9(1):18-25
references.pmid: 24346090
references.citation: J Clin Oncol. 2014 Sep 1;32(25):2780-7
references.pmid: 25071109
references.citation: J Mol Diagn. 2013 May;15(3):341-6
references.pmid: 23499337
references.citation: J Clin Oncol. 2009 Sep 10;27(26):4247-53
references.pmid: 19667264
references.citation: N Engl J Med. 2013 Jun 20;368(25):2385-94
references.pmid: 23724913
references.citation: Mod Pathol. 2009 Apr;22(4):508-15
references.pmid: 19234440
references.citation: J Thorac Oncol. 2014 Jan;9(1):109-13
references.pmid: 24346098
references.citation: PLoS One. 2014 Jul 03;9(7):e101551
references.pmid: 24992725
references.citation: Ann Oncol. 2013 Oct;24(10):2589-93
references.pmid: 23904459
references.citation: Nature. 2007 Aug 2;448(7153):561-6
references.pmid: 17625570